基于敏感预测标志物的肿瘤个体化治疗已经在临床上取得成功并被广泛认可，但原发性及获得性耐药的出现严重制约了靶向药物的临床真正有效率。为解决这一问题，我们提出同步开发疗效监控标志物并开展集合分子诊断与分子监控为一体的新型个体化治疗模式，并系统证明了c-Myc可作为激酶抑制剂的疗效监控标志物，对疗效响应、预测耐药产生及克服耐药等方面提供合理指导。在此基础上拟进一步从分子影像探针和血液检测指标两个方面、通过直接和间接两种策略，借助高通量筛选和c-Myc调控基因分析等手段，开发新的基于c-Myc调控的无创性检测体系。通过本研究，有望获得数个分子影像探针实体或细胞因子组合，从而实现针对c-Myc的无创检测，为后续的临床实践提供重要参考。

The pratice of predictive biomarker guided personalized medicine for cancer threapy has been well recognized in recent years, however, the overall clinical benifit ratio remaines obscue which results from frequently occured primary and acquired resistance. Hence, we proposed the new concept of rsponse biomarker to solve this problem and systemly discovered c-Myc as a powerful response biomarker for kinase inhibitors to dictate drug response and resistance. In this study, we developed several strategies, such as imaging c-Myc directly or its targeted proteins indirectly and detecting c-Myc regulated cytokines in serum to improve the clincal application of c-Myc in a non-invasive way.